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Recent studies suggest that correcting low serum
bicarbonate levels may reduce the progression of kidney
disease; however, few patients with chronic kidney disease
have low serum bicarbonate. Therefore, we examined
whether higher levels of serum bicarbonate within the
normal range (20–30mmol/l) were associated with better
kidney outcomes in the African American Study of Kidney
Disease and Hypertension (AASK) trial. At baseline and
during follow-up of 1094 patients, the glomerular filtration
rates (GFR) were measured by iothalamate clearances and
events were adjudicated by the outcomes committee. Mean
baseline serum bicarbonate, measured GFR, and proteinuria
were 25.1mmol/l, 46ml/min per 1.73m2, and 326mg/g of
creatinine, respectively. Each 1mmol/l increase in serum
bicarbonate within the normal range was associated with
reduced risk of death, dialysis, or GFR event and with dialysis
or GFR event (hazard ratios of 0.942 and 0.932, respectively)
in separate multivariable Cox regression models that
included errors-in-variables calibration. Cubic spline
regression showed that the lowest risk of GFR event or
dialysis was found at serum bicarbonate levels near
28–30mmol/l. Thus, our study suggests that serum
bicarbonate is an independent predictor of CKD progression.
Whether increasing serum bicarbonate into the high-normal
range will improve kidney outcomes during interventional
studies will need to be considered.
Kidney International (2011) 79, 356–362; doi:10.1038/ki.2010.388;
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Long-term follow-up of participants in the African American
Study of Kidney Disease and Hypertension (AASK) showed
that 450% died or developed a doubling of serum creatinine
or end-stage renal disease at 10 years of follow-up.1,2 This is
particularly concerning as 480% of participants in the
cohort phase of AASK were on renin–angiotensin blockers
and blood pressure was maintained near recommended
target values.1 Given that most patients with chronic kidney
disease (CKD) progress over the long term, it is clear that
other strategies are necessary to slow advancing CKD.
In addition to renin–angiotensin blockade, correcting
metabolic acidosis might be a useful additional maneuver to
prevent CKD progression. Metabolic acidosis resulting from
impaired urinary acid excretion is a complication of CKD.
There are some data suggesting a detrimental effect of low
serum bicarbonate with outcomes in CKD. In a recent study,
individuals with hypertensive nephropathy and serum
bicarbonate o22 mmol/l treated with sodium citrate had
improved surrogate markers of kidney disease, such as
reduced urinary excretion of endothelin-1, transforming
growth factor-b1, and albumin, compared with those who
were not treated with alkali.3 In a randomized study of 134
CKD patients with serum bicarbonate levels in the range of
16–20 mmol/l, correcting low serum bicarbonate reduced
the rate of kidney function decline when compared with
placebo.4 Thus, those CKD patients with overt reduction in
serum bicarbonate levels might benefit from correction
of low serum bicarbonate levels. However, 485% of people
with estimated glomerular filtration rate (eGFR) in the range
of 30–49 ml/min per 1.73 m2 and 475% of those with eGFR
in the range of 20–29 ml/min per 1.73 m2 do not have low
serum bicarbonate (o22 mmol/l).5 Thus, it is important to
examine whether serum bicarbonate in the upper limit of
normal range is associated with better outcomes.
In a retrospective chart review of 5422 adults visiting a
general medical clinic, compared with those with serum
bicarbonate levels of 25–26 mmol/l, the low serum bicarbo-
nate (o22 mmol/l) group had a higher hazard of kidney
disease progression after adjusting for eGFR.6 In a study of
1106 veterans with mean eGFR of 37±17 ml/min per
1.73 m2, the lowest hazard of death was in those with
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baseline serum bicarbonate levels of 24–29 mmol/l, but the
associations of serum bicarbonate with kidney outcomes
were not specifically reported.7 These studies used GFR
estimated from serum creatinine by the modification of diet
in renal disease (MDRD) equation to adjust for confounding
among the level of renal impairment, serum bicarbonate,
and the outcomes. Even though these analyses controlled
for eGFR, it is possible that lower serum bicarbonate levels
might still reflect low true GFR,8 and therefore, these
observational results could still be confounded by the level
of kidney function. This report of the AASK cohort investi-
gates the hypothesis that higher serum bicarbonate levels
within the normal range are associated with improved renal
outcomes, while rigorously controlling for GFR using
iothalamate clearance, rather than eGFR, and other potential
confounders.
RESULTS
Baseline characteristics
Characteristics of AASK study participants according to
baseline serum bicarbonate (o20 mmol/l, 20–24.9 mmol/l,
25–29.9 mmol/l, and X30 mmol/l) are presented in Table 1.
Only 4.3% of the AASK cohort (mean GFR 34±13 ml/min
per 1.73 m2) had serum bicarbonate levels o20 mmol/l,
whereas 35.5% had serum bicarbonate in the low-normal
range (20–24.9 mmol/l). The lowest serum bicarbonate group
had lower mean GFR and higher median baseline proteinur-
ia. Body mass index was lower in the lowest bicarbonate
group. Only 39% of the participants in the lowest
bicarbonate group, but 83% of the participants in the highest
bicarbonate group, were on diuretics at baseline.
Death, dialysis, or GFR event composite in entire cohort
There were a total of 359 death, dialysis, or GFR composite
events occurring over 4475 patient-years of follow-up (0.08
events per patient-year). The unadjusted cumulative in-
cidence of this outcome by serum bicarbonate groups is
shown in Figure 1. The event rates for those with baseline
serum bicarbonate o20, 20–24.9, 25–29.9, and X30 mmol/l
were 0.17, 0.10, 0.06, and 0.06 events per patient-year,
respectively.
To account for confounding between serum bicarbonate
and other baseline factors, the association of serum
bicarbonate with the composite outcome was next examined
in Cox models (Table 2). After adjusting for age, gender, and
randomization groups, each 1 mmol/l increase in serum
bicarbonate was associated with an 11.1% reduction in the
hazard of the clinical composite outcome of death, dialysis,
or GFR events (hazard ratio (HR) 0.889, 95% confidence
interval (CI) 0.859–0.921). Further adjustment for baseline-
measured iothalamate GFR and proteinuria attenuated, but
did not eliminate this association (HR 0.950, 95% CI
0.916–0.985). Even though GFR was measured directly based
on iothalamate clearance in this cohort, recognizing that
there could be errors in measurements of both proteinuria
and GFR, we next built an errors-in-measurement Cox
regression model adjusting for these covariables. The
associations of serum bicarbonate with the above composite
outcome remained significant in that model (Table 2).
In sensitivity analyses, when further adjusted for baseline
atherosclerotic conditions, congestive heart failure, mean
arterial blood pressure, body mass index, smoking, serum
albumin, and use of diuretics, each 1 mmol/l increase in
Table 1 | Characteristics of AASK participants by baseline serum bicarbonate
Serum HCO3

(o20mmol/l)
Serum HCO3

(20–24.9mmol/l)
Serum HCO3

(25–29.9mmol/l)
Serum HCO3

(X30mmol/l) P-value
Number 47 388 599 60
Age (years) 54±11 54±11 55±10 55±10 0.167
Male (%) 51.1 62.4 61.3 60.0 0.514
Randomized drug group (%)
Ramipril 34.0 42.3 39.2 35.0 0.514
Metoprolol 38.3 40.5 41.1 33.3 0.696
Amlodipine 27.7 17.3 19.7 31.7 0.034
Randomized BP group (%)
Strict control 46.8 51.0 48.4 50.0 0.854
Usual control 53.2 49.0 51.6 50.0 0.854
Atherosclerotic conditions (%) 12.8 12.1 16.1 10.0 0.259
Congestive heart failure (%) 4.3 2.6 2.3 3.3 0.849
Current or past smoking (%) 63.8 62.4 54.9 53.3 0.088
Body mass index (kg/m2) 26.8±6.5 30.5±6.5 30.8±6.5 31.8±7.1 o0.001
Mean arterial pressure (mmHg) 116±16 113±15 114±16 117±19 0.286
GFR (ml/min per 1.73m2) 34±13 43±14 49±13 49±12 o0.001
Urine protein/creatinine
ratio (mg/g)a
410 (50, 1110) 130 (40, 580) 60 (20, 230) 70 (30, 260) o0.001
Serum albumin (g/dl) 4.2±0.3 4.2±0.4 4.3±0.4 4.3±0.4 0.019
Diuretic use (%) 39.1 61.6 65.1 83.1 o0.001
Abbreviations: AASK, African American Study of Kidney Disease and Hypertension; ANOVA, analysis of variance; BP, blood pressure; GFR, glomerular filtration rate.
aMedian (interquartile range) presented.
P-values are calculated by ANOVA for continuous variables and w2-values for dichotomous variables. Continuous measures are shown as mean±standard error.
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serum bicarbonate was associated with a statistically
significant 4% lower hazard of the composite death, dialysis,
or GFR event (Table 2).
The results of a restricted cubic spline regression model
adjusted for gender, age, trial assignment, GFR, and
proteinuria are presented in Figure 2, which shows a linear
inverse relationship between serum bicarbonate levels and the
death, dialysis, or GFR event composite.
Dialysis or GFR event composite in entire cohort
The unadjusted cumulative incidence of the dialysis or GFR
event composite was also higher in the lowest bicarbonate
group (Figure 3). There were a total of 278 events occurring
over 4475 patient-years of follow-up (0.06 events per patient-
year). The event rates for those with baseline bicarbonate
o20, 20–24.9, 25–29.9, and X30 mmol/l were 0.15, 0.10,
0.05, and 0.05 events per patient-year, respectively.
Each 1 mmol/l increase in serum bicarbonate was
associated with a 6% lower hazard of the composite renal
outcome of dialysis or GFR event (HR 0.940, 95% CI
0.902–0.980) after adjusting for age, gender, trial assignment,
GFR, and proteinuria. This relationship persisted despite
extensive adjustment for measurement error and extended
covariables (Table 3). Results of a restricted cubic spline
regression model adjusted for gender, age, trial assignment,
GFR, and proteinuria suggest that the lowest risk of dialysis
or GFR event is at serum bicarbonate levels in the range of
28–30 mmol/l (Figure 4).
Death in entire cohort
There were a total of 105 deaths (including deaths after end-
stage renal disease) occurring over 4475 patient-years of
follow-up (0.02 events per patient-year). There were no
associations of serum bicarbonate with death (HR 0.987,
95% CI 0.923–1.056 for each 1 mmol/l increase in serum
bicarbonate) in a Cox model adjusted for demographics, trial
assignment, GFR, and proteinuria.
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Figure 1 |Probability of death or renal composite (dialysis or
glomerular filtration rate (GFR) event) according to baseline
serum bicarbonate levels. Participants were categorized into
four groups according to the baseline bicarbonate levels
(o20mmol/l, 20.0–24.9mmol/l, 25.0–29.9mmol/l, and
X30mmol/l). The unadjusted results are shown here.
Table 2 | Association of each mmol/l increase in baseline serum bicarbonate with the hazard of death, dialysis, or GFR event in
the entire cohort (N=1090) and those with baseline serum bicarbonate levels of 20–30mmol/l (N=1017)
Death, dialysis, or GFR event
Entire cohort 20–30mmol/l
Baseline HCO3
 HR 95% CI P-value HR 95% CI P-value
Model 1a 0.889 0.859–0.921 o0.0001 0.869 0.829–0.910 o0.0001
Model 2b 0.950 0.916–0.985 0.006 0.938 0.894–0.984 0.009
Model 3c 0.956 0.921–0.992 0.018 0.942 0.898–0.989 0.017
Model 4d 0.960 0.924–0.998 0.041 0.950 0.904–0.999 0.047
Abbreviations: CI, confidence interval; GFR, glomerular filtration rate; HR, hazard ratio.
aModel 1: adjusted for age, gender, and blood pressure and drug assignment.
bModel 2: adjusted for Model 1 variables, GFR, and proteinuria at baseline.
cModel 3: adjusted for Model 2 variables and accounting for measurement error in baseline GFR and proteinuria.
dModel 4: adjusted for Model 3 variables, atherosclerotic conditions, congestive heart failure, mean arterial blood pressure, body mass index, smoking, serum albumin, and
use of diuretics at baseline.
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Figure 2 |Restricted cubic spline regression model of the
hazard of glomerular filtration rate (GFR) event, dialysis, or
death among all participants by baseline serum bicarbonate
levels after adjusting for gender, age, trial assignment,
measured GFR, and proteinuria. The estimated adjusted hazard
ratio as a function of baseline serum bicarbonate, using a
bicarbonate level of 20mmol/l as the reference, with 95%
pointwise confidence limits, is shown here.
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Serum bicarbonate in the normal range and outcomes
Figures 2 and 4 suggest that higher serum bicarbonate levels
within the range of 20–30 mmol/l were associated with
improved survival and renal outcomes. We further examined
these in analyses restricted to those with baseline serum
bicarbonate levels of 20–30 mmol/l (n¼ 1017). Cox regres-
sion models were carried out in the same fashion as described
above and the results are summarized in Tables 2 and 3.
These results suggest that even after extensive adjustment,
each 1 mmol/l increase in baseline serum bicarbonate
levels within the range of 20–30 mmol/l was associated
with reduced risk of the composite of death, dialysis, or
GFR event, as well as composite renal outcomes of dialysis
or GFR event.
Sensitivity analyses
We conducted additional sensitivity analyses with adjusting
for baseline eGFR estimated from the four-variable MDRD
equation. These results were qualitatively similar to the
models using iothalamate-measured GFR. For each 1 mmol/l
increase in serum bicarbonate, the hazard of death, dialysis,
or GFR event was lower (HR 0.958, 95% CI 0.924–0.993) in
a multivariable Cox regression model adjusted for demo-
graphics, trial characteristics, baseline proteinuria, and
eGFR. In additional sensitivity analyses of anion gap, the
Pearson correlation coefficient between anion gap and serum
bicarbonate was low at 0.14, even though it was statistically
significant (Po0.0001). The R2 was 0.0196, indicating that
o2% of the variability in serum bicarbonate was explained
by anion gap. After adjustment for demographics and trial
assignment, iothalamate-derived GFR, and proteinuria,
anion gap was not associated with the death, dialysis, or
GFR event composite (HR 0.991, 95% CI 0.949–1.036 for
each unit increase in anion gap), or with dialysis or GFR
event composite (0.989, 95% CI 0.940–1.040 for each unit
increase in anion gap HR). Because protein intake might
influence serum bicarbonate, a final sensitivity analysis
was performed in which we adjusted for demographics,
trial assignment, iothalamate-derived GFR, proteinuria,
and calculated protein intake. Inclusion of calculated protein
intake in the Cox models had no effect on the associations
of serum bicarbonate with death, dialysis, or GFR event
composite (for each mmol/l increase in serum bicarbonate:
HR 0.950, 95% CI 0.916–0.986) and with the dialysis or GFR
event composite (for each mmol/l increase in serum
bicarbonate: HR 0.941, 95% CI 0.902–0.981) in the entire
cohort (please see Model 2 in Tables 2 and 3 for comparison).
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Figure 3 |Probability of the renal composite (dialysis or
glomerular filtration rate (GFR) event) according to baseline
serum bicarbonate levels. Participants were categorized into
four groups according to the baseline bicarbonate levels
(o20mmol/l, 20.0–24.9mmol/l, 25.0–29.9mmol/l, and
X30mmol/l). The unadjusted results are shown here.
Table 3 | Association of each mmol/l increase in baseline
serum bicarbonate with the hazard of dialysis or GFR event
in the entire cohort (N=1090) and those with baseline serum
bicarbonate levels of 20–30mmol/l (N=1017)
Dialysis or GFR event
Entire cohort 20–30mmol/l
Baseline HCO3
 HR 95% CI P-value HR 95% CI P-value
Model 1a 0.872 0.838–0.907 o0.0001 0.851 0.806–0.898 o0.0001
Model 2b 0.940 0.902–0.980 0.004 0.927 0.877–0.980 0.007
Model 3c 0.947 0.907–0.988 0.012 0.932 0.881–0.986 0.014
Model 4d 0.951 0.909–0.994 0.027 0.939 0.885–0.996 0.035
Abbreviations: CI, confidence interval; GFR, glomerular filtration rate; HR, hazard
ratio.
aModel 1: adjusted for age, gender, and blood pressure and drug assignment.
bModel 2: adjusted for Model 1 variables, GFR, and proteinuria at baseline.
cModel 3: adjusted for Model 2 variables and accounting for measurement error in
baseline GFR and proteinuria.
dModel 4: adjusted for Model 3 variables, atherosclerotic conditions, congestive
heart failure, mean arterial blood pressure, body mass index, smoking, serum
albumin, and use of diuretics at baseline.
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Figure 4 |Restricted cubic spline regression model of the
hazard of glomerular filtration rate (GFR) event or dialysis
among all participants by baseline serum bicarbonate levels
after adjusting for gender, age, trial assignment, measured
GFR, and proteinuria. The estimated adjusted hazard ratio as a
function of baseline serum bicarbonate, using a bicarbonate level
of 20mmol/l as the reference, with 95% pointwise confidence
limits, is shown here.
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DISCUSSION
The Kidney Disease Outcome Quality Initiative practice
guidelines recommend that serum bicarbonate be kept at a
minimum of 22 mmol/l in those with CKD, a cutoff chosen
based on the effect of metabolic acidosis on metabolic bone
disease and nutritional parameters.9 However, the optimum
serum bicarbonate in CKD might be different when consi-
dering renal and survival outcomes than for metabolic bone
disease. In this investigation of the association of baseline
serum bicarbonate on survival and renal outcomes in African
Americans with hypertensive, non-dialysis-dependent CKD,
higher serum bicarbonate is associated with reduced hazard
of CKD progression and mortality. More importantly, in
those within the range of serum bicarbonate levels of
20–30 mmol/l, there was an inverse linear relationship
between serum bicarbonate levels and the hazard of death,
dialysis, or GFR event composite, as well as dialysis or GFR
event composite (Tables 2 and 3 and Figures 2 and 4), with
the lowest hazard of kidney events observed as serum
bicarbonate levels approach 30 mmol/l.
A strength of this study is that we have carefully
considered confounding between baseline renal function
and serum bicarbonate on the clinical end points. Prior
studies investigating the association of baseline serum
bicarbonate levels with CKD progression and mortality used
the MDRD formula to estimate GFR.6,7 However, the
accuracy of the MDRD equation was only 83%, even when
accuracy was defined as predicting the measured GFR within
a range of ±30%.10 Thus, eGFR may be substantially
different from measured GFR in an individual. In a study in
which the associations of serum bicarbonate with subsequent
outcomes could largely reflect the associations of serum
bicarbonate with baseline GFR, it is important that the
baseline GFR be determined as accurately as possible.
Furthermore, we recognize that there could be random
measurement errors of GFR and proteinuria, which are
important confounders of the hypothesis tested in this study.
Therefore, we used additional errors-in-variables regression
models to account for this. The results of this study suggest
that after taking all of the above issues into account, the
associations of baseline serum bicarbonate with clinical
outcomes is not confounded by the level of baseline kidney
function. These results support the results of prior studies
that investigated the associations of baseline serum bicarbo-
nate with CKD progression or mortality using the MDRD
formula to estimate GFR.6,7
A major goal of this analysis is to describe the relationship
between serum bicarbonate levels in the 20–30 mmol/l range
with the outcomes in CKD. An earlier study suggested that
correcting low serum bicarbonate (16–20 mmol/l) in CKD
was associated with better renal outcomes.4 However, most
patients with CKD do not have serum bicarbonate at such
low levels, as was apparent in this study, in which o5% of
this advanced CKD cohort had serum bicarbonate levels
o20 mmol/l. This analysis supports the notion that baseline
serum bicarbonate levels in the higher end of the normal
range is associated with improved long-term renal function.
These data suggest that individuals with CKD and serum
bicarbonate in the low-normal range might also derive
benefit from alkali therapy. Furthermore, maintaining serum
bicarbonate in the high-normal range might improve long-
term renal outcomes rather than maintaining it at a
minimum of 22 mmol/l.
The potential mechanism explaining the finding that the
lowest hazard of CKD progression is in the upper range of
normal is speculative, but may involve renal ammonia
production. Nath et al.11 showed that metabolic acidosis
increases renal ammonia production, activates the alternative
complement pathway, and contributes to tubulointerstitial
injury in a remnant kidney model. However, increased renal
ammonia production has been observed in animals with
normal serum bicarbonate levels after renal ablation–
infarction, presumably as a means to maintain normal
systemic acid–base balance.12 Thus, if serum bicarbonate
levels are in the range of 28–30 mmol/l, renal ammonia
production and tubulointerstitial fibrosis might be maxi-
mally attenuated. Therefore, administration of alkali in early
stages of CKD, when serum bicarbonate is in the normal
range, might reduce ammonia generation and provide a
means to slow tubulointerstitial fibrosis.
Other effects of chronic metabolic acidosis include
metabolic bone disease, skeletal muscle wasting, hypoalbu-
minemia, insulin resistance, abnormal thyroid function, and
elevated C-reactive protein.13–17 In non-dialysis-dependent
CKD, treating metabolic acidosis attenuates elevations in
parathyroid hormone,18 reduces protein degradation,19
reduces blood urea nitrogen,20,21 and raises 1,25-dihydroxy-
vitamin D levels.22
Although this study and a prior study7 suggest that the
optimal serum bicarbonate range is about 28–30 mmol/l in
the CKD population, the optimal range of serum bicarbonate
in dialysis patients might be lower. In two hemodialysis
studies, the lowest hazard of death was associated with serum
bicarbonate levels of 20–22 mmol/l.23,24 However, in another
study of hemodialysis patients, those with serum bicarbonate
422 mmol/l had lower hazard of death.25
The AASK trial was designed to examine the effects of
blood pressure control and blood pressure agents on the
slope of GFR decline. Hence, a limitation of our study is that
it is a secondary analysis of an existing database. It is also
possible that the serum bicarbonate level could have been
falsely low in some participants at baseline owing to delays in
centrifugation of the blood sample and the measurement of
total CO2,
26 as samples were analyzed at a central laboratory.
In addition, higher serum bicarbonate levels might reflect
compensation for respiratory acidosis. However, if indeed
this is the case, there are no biological rationale for how
respiratory acidosis is associated with improved survival and
reduced kidney disease progression in CKD.
In summary, the results of this investigation suggest that
higher serum bicarbonate levels within the normal range are
associated with reduced hazard of mortality and CKD
360 Kidney International (2011) 79, 356–362
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progression. Furthermore, serum bicarbonate level is an
independent predictor of CKD progression. Interventional
trials are warranted to determine the renoprotective effects of
maintaining serum bicarbonate levels between 28 and
30 mmol/l in individuals with CKD.
METHODS
Study participants
The details of the AASK trial have been published earlier.1,2,27
African Americans, aged 18 to 70 years, with hypertensive CKD
(defined by a GFR between 20 and 65 ml/min per 1.73 m2 by renal
clearance of iodine I125 iothalamate clearance and diastolic blood
pressure 495 mm Hg) were eligible for the study. Patients were
excluded if they had elevated fasting or random blood glucose,
treatment for diabetes, urinary protein to creatinine ratio of 42.5,
accelerated or malignant hypertension, serious systemic disease,
congestive heart failure, or a specific indication for or contra-
indication to a study drug.
AASK trial
The AASK study was a 3 2 factorial design. Participants were
randomized to ramipril, metoprolol, or amlodipine, and to one of
two blood pressure goals (a usual mean arterial pressure of
102–107 mm Hg or a low mean arterial pressure goal of
p92 mm Hg). Recruitment into the full-scale trial began in
February 1995, with planned follow-up through to September
2001. Using standardized forms, trained personnel obtained data on
baseline demographic, clinical, and laboratory data. At a seated
position, 10–20 ml of blood was collected in serum separator tubes,
allowed to clot at room temperature for at least 30 min, and then
centrifuged. Serum samples were mailed overnight in a frozen
pack to the Central Biochemistry Laboratory at the Cleveland Clinic
for standardized measurements. Serum bicarbonate was measured
using either the kinetic ultraviolet method (Roche Hitachi 747
autoanalyzer, Roche, Indianapolis, IN) or a CO2 electrode (Beckman
CX3 Delta autoanalyzer, Beckman, Brea, CA). Urinary protein
excretion was expressed as the urinary protein to creatinine ratio
from a 24-h urine collection. The primary outcome was the rate of
change in iothalamate GFR, which was measured twice during
baseline, and at months 3, 6, and every 6 months thereafter for a 3.5-
to 6.5-year follow-up period. A main secondary outcome was a
composite of death, end-stage renal disease (dialysis or transplanta-
tion), or GFR event (defined as a GFR reduction by 50% or by
25 ml/min per 1.73 m2 from the mean of two GFR measurements at
baseline). The outcomes committee adjudicated the above events.
Statistical analysis
Baseline characteristics were summarized and compared between
the four serum bicarbonate groups (defined a priori using clinical
criteria) using independent two-sample t-tests or Wilcoxon rank-
sum tests as appropriate for continuous variables and Fisher’s exact
test for categorical variables.
Examination of death, dialysis, or GFR event composite
A series of Cox regression models were fit to relate the clinical
composite outcome of GFR event, dialysis, and death to serum
bicarbonate as a continuous variable using different levels of
covariate adjustment, with stratification of the baseline hazard by
clinical center. Follow-up time was censored at the administrative
end date of the study and permanent loss-to-follow-up. The initial
model included only the AASK intervention groups and the basic
demographic factors of age and gender as covariates. Next, as the
most important biological confounder of the associations of serum
bicarbonate with outcomes is baseline level of kidney function, this
model was adjusted for the mean of the two baseline measurements
of iothalamate GFR and logarithm of the baseline 24-h urinary
protein to creatinine ratio. A two-slope spline model was used for
iothalamate GFR, with separate slope below and above 40 ml/min
per 1.73 m2, because the association of GFR with the clinical
composite was found to be stronger at lower than at higher GFR
levels.
In the third step, an errors-in-variables regression calibration
approach28 was applied to the Cox regression from step 2 to adjust
for measurement error in the iothalamate GFR and log-transformed
urine protein to creatinine measurements. This step was necessary
because both these variables have nontrivial random variation, so
that conventional Cox regression analysis without an errors-in-
variables adjustment may not fully control for confounding between
bicarbonate and baseline renal function. Based on the observed
variation in measured GFR between the two baseline assessments,
and the average variation between log-transformed urine
protein to creatinine ratio over 6-month interval in the follow-up
period of the trial, the regression calibration model assumed
measurement error variances of 0.0146 for log-transformed GFR
and of 0.324 for log-transformed urine protein/creatinine ratio. The
variance estimates correspond roughly to assumed coefficients of
variation of 15 and 58% for GFR and urine protein/creatinine ratio,
respectively, and reflect both assay measurement error and short-
term biological fluctuations. In the last step, atherosclerotic
conditions, congestive heart failure, mean arterial pressure, smok-
ing, body mass index, serum albumin, and use of diuretics at
baseline were added to the above model. The results of the final
model were interpreted as exploratory, as we recognized that some
of these additional factors could be on the causal pathway between
effects of bicarbonate and renal outcome (thus leading to a risk of
overadjustment).
To examine whether higher serum bicarbonate levels in the
normal range (20–30 mmol/l) were associated with better
outcomes, two approaches were adopted. In the first approach,
the above Cox regression models were examined in the sub-group
of patients with serum bicarbonate levels in the 20–30 mmol/l
range. In the second approach, we modified the above Cox
regression analyses by using a four-degree of freedom restricted
cubic regression spline basis matrix to graphically model the
relationship between serum bicarbonate levels and the clinical
composite outcome.29 Because the cubic splines provided smooth
functions over the range of serum bicarbonate in the data set, the
results are relatively insensitive to the selection of the knot points.
This analysis was run with adjustment for age, gender, trial
assignment, iothalamate-measured GFR, and logarithm of urinary
protein to creatinine ratio, using serum bicarbonate of 20 mmol/l as
the reference.
Examination of dialysis or GFR event composite
The above analyses were repeated with dialysis or GFR event
composite as the outcome of interest.
Examination of death
The above analyses were repeated with death as the outcome of
interest. Deaths included those that occurred after the onset of end-
stage renal disease.
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Sensitivity analyses
Baseline GFR estimated from the four-variable MDRD equation was
used instead of the iothalamate GFR to examine the associations of
serum bicarbonate with the composite outcomes in Cox models.
Correlation between anion gap (calculated as the difference
between sodium and the sum of chloride and bicarbonate) and
bicarbonate was tested using a Pearson correlation coefficient. In
an additional set of analyses, anion gap was used instead of
serum bicarbonate as the predictor variable in Cox models of
time to death, dialysis, or GFR event composite or dialysis or GFR
event composite.
Estimated protein intake was calculated from the baseline 24-h
urine urea nitrogen excretion by the formula 6.25(urine urea nitrogen
in g/dayþ (0.031 g nitrogen/kilogram/day)(weight in kg)).30
In all of the above models, key assumptions of the Cox regression
models, including linear effects of baseline factors and proportional
hazards over time, were evaluated by preliminary diagnostic
analyses. First, quadratic terms were tested for each continuous
covariate to test for the presence of nonlinear effects of continuous
covariates. Only GFR and albumin had nonlinear associations with
the outcomes. Therefore, both linear and quadratic terms were
included for these variables in each of the Cox regressions described
above. Second, interactions of each predictor with follow-up time
were tested to evaluate the assumption of proportional hazards. No
significant deviation from proportional hazards was detected.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
The AASK study was conducted by the AASK investigators and
supported by the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK). This manuscript was not prepared in
collaboration with investigators of the AASK study and does not
necessarily reflect the opinions of the AASK study or the NIDDK.
This work is supported by NIDDK Grants RO1-DK077298 and
RO1-DK078112 awarded to SB.
REFERENCES
1. Appel LJ, Wright Jr JT, Greene T et al. Long-term effects of renin-
angiotensin system-blocking therapy and a low blood pressure goal on
progression of hypertensive chronic ki kidney disease in African
Americans. Arch Intern Med 2008; 168: 832–839.
2. Wright Jr JT, Bakris G, Greene T et al. Effect of blood pressure lowering
and antihypertensive drug class on progression of hypertensive kidney
disease: results from the AASK trial. JAMA 2002; 288: 2421–2431.
3. Phisitkul S, Khanna A, Simoni J et al. Amelioration of metabolic acidosis in
patients with low GFR reduced kidney endothelin production and kidney
injury, and better preserved GFR. Kidney Int 2010; 77: 617–623.
4. de Brito-Ashurst I, Varagunam M, Raftery MJ et al. Bicarbonate
supplementation slows progression of CKD and improves nutritional
status. J Am Soc Nephrol 2009; 20: 2075–2084.
5. Moranne O, Froissart M, Rossert J et al. Timing of onset of CKD-related
metabolic complications. J Am Soc Nephrol 2009; 20: 164–171.
6. Shah SN, Abramowitz M, Hostetter TH et al. Serum bicarbonate levels and
the progression of kidney disease: a cohort study. Am J Kidney Dis 2009;
54: 270–277.
7. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum
bicarbonate levels with mortality in patients with non-dialysis-dependent
CKD. Nephrol Dial Transplant 2009; 24: 1232–1237.
8. Chertow GM, Moe SM. Calcification or classification? J Am Soc Nephrol
2005; 16: 293–295.
9. Clinical practice guidelines for nutrition in chronic renal failure. K/DOQI,
National Kidney Foundation. Am J Kidney Dis 2000; 35: S1–S140.
10. Stevens LA, Coresh J, Feldman HI et al. Evaluation of the modification
of diet in renal disease study equation in a large diverse population.
J Am Soc Nephrol 2007; 18: 2749–2757.
11. Nath KA, Hostetter MK, Hostetter TH. Pathophysiology of chronic tubulo-
interstitial disease in rats. Interactions of dietary acid load, ammonia, and
complement component C3. J Clin Invest 1985; 76: 667–675.
12. Kim HY, Baylis C, Verlander JW et al. Effect of reduced renal mass on renal
ammonia transporter family, Rh C glycoprotein and Rh B glycoprotein,
expression. Am J Physiol Renal Physiol 2007; 293: F1238–F1247.
13. Brungger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on
thyroid hormone homeostasis in humans. Am J Physiol 1997; 272:
F648–F653.
14. Clase CM, Kiberd BA, Garg AX. Relationship between glomerular filtration
rate and the prevalence of metabolic abnormalities: results from the
Third National Health and Nutrition Examination Survey (NHANES III).
Nephron Clin Pract 2007; 105: c178–c184.
15. Farwell WR, Taylor EN. Serum bicarbonate, anion gap and insulin
resistance in the National Health and Nutrition Examination Survey.
Diabet Med 2008; 25: 798–804.
16. Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical
characteristics, and treatment. Am J Kidney Dis 2005; 45: 978–993.
17. Lofberg E, Gutierrez A, Anderstam B et al. Effect of bicarbonate on muscle
protein in patients receiving hemodialysis. Am J Kidney Dis 2006; 48:
419–429.
18. Mathur RP, Dash SC, Gupta N et al. Effects of correction of metabolic
acidosis on blood urea and bone metabolism in patients with mild to
moderate chronic kidney disease: a prospective randomized single blind
controlled trial. Ren Fail 2006; 28: 1–5.
19. Reaich D, Channon SM, Scrimgeour CM et al. Correction of acidosis in
humans with CRF decreases protein degradation and amino acid
oxidation. Am J Physiol 1993; 265: E230–E235.
20. Jenkins D, Burton PR, Bennett SE et al. The metabolic consequences of
the correction of acidosis in uraemia. Nephrol Dial Transplant 1989; 4:
92–95.
21. Papadoyannakis NJ, Stefanidis CJ, McGeown M. The effect of the
correction of metabolic acidosis on nitrogen and potassium balance of
patients with chronic renal failure. Am J Clin Nutr 1984; 40: 623–627.
22. Lu KC, Lin SH, Yu FC et al. Influence of metabolic acidosis on serum
1,25(OH)2D3 levels in chronic renal failure. Miner Electrolyte Metab 1995;
21: 398–402.
23. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum
bicarbonate levels with risk of mortality and hospitalization in the Dialysis
Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44:
661–671.
24. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive
value of commonly measured variables and an evaluation, of death rate
differences between facilities. Am J Kidney Dis 1990; 15: 458–482.
25. Wu DY, Shinaberger CS, Regidor DL et al. Association between serum
bicarbonate and death in hemodialysis patients: is it better to be acidotic
or alkalotic? Clin J Am Soc Nephrol 2006; 1: 70–78.
26. Kirschbaum B. Spurious metabolic acidosis in hemodialysis patients.
Am J Kidney Dis 2000; 35: 1068–1071.
27. Gassman JJ, Greene T, Wright Jr JT et al. Design and statistical aspects
of the African American Study of Kidney Disease and Hypertension
(AASK). J Am Soc Nephrol 2003; 14: S154–S165.
28. Carroll R, Ruppert D, Stefanski LA et al. Measurement Error in Nonlinear
Models: A Modern Perspective, Second Edition, 2nd edn Chapman & Hall:
Florence, KY, 2006.
29. Heinzl H, Kaider A, Zlabinger G. Assessing interactions of binary
time-dependent covariates with time in Cox proportional hazards
regression models using cubic spline functions. Stat Med 1996; 15:
2589–2601.
30. Maroni BJ, Steinman TI, Mitch WE. A method for estimating
nitrogen intake of patients with chronic renal failure. Kidney Int 1985; 27:
58–65.
362 Kidney International (2011) 79, 356–362
or ig ina l a r t i c l e KL Raphael et al.: Bicarbonate, death and CKD progression
